The new heart failure drug ‘Verquvo’ is busy securing prescriptions in Korea with its reimbursement listing.

According to industry sources, Bayer Korea’s soluble Guanylate Cyclase (sGC) stimulator Verquvo (Vericiguat)’ passed the drug committees of Korea Anam Hospital, Chung-Ang University Gwangmyeong Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Pusan National University Hospital at Yangsan, Yeosu Jeil Hospital, Ewha Womans University Mokdong Hospital, Chonnam National University Hospital, etc.

Bayer is currently undergoing review processes at other major general hospitals and plans to make Verquvo’s prescription available at most hospitals nationwi